Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1969 - 1976 of 11456 results
Energy & Sustainability Legal Feature — Massachusetts Approves $4B 2022–2024 Efficiency Plan
March 8, 2022| Article| Viewpoint
ONC Publishes Report, Commentary on Information Blocking Rule Claims Trends
March 7, 2022| News
Health Plan Transparency and the Case for Welfare Plan Fiduciary Committees
March 7, 2022| Blog| Viewpoint
What's New in 5G - March 2022
March 3, 2022| News
Mintz’s Sell-Side Series: Preparing Today for Tomorrow's Sale — Week 1
March 3, 2022| Article| Viewpoint
No Harm, No Foul, and No Standing for Would-be SEP Implementer: 5th Circuit Changes Narrative on Patent “Hold Up”
March 3, 2022| Blog| Viewpoint
Health Law Diagnosed — Transactions Part 1: Regulatory Trends in Recent Health Care Transactions
March 3, 2022| Podcast| Viewpoint
What Does ESG Mean for Your Organization?
March 3, 2022| Webinar| Viewpoint
News & Press Releases
Mintz is pleased to announce that 31 attorneys have been named Massachusetts Super Lawyers and 35 attorneys have been named Massachusetts Rising Stars for 2024.
Mintz IP Group Named “Litigation Department of the Year” in 2024 New England Legal Awards
October 02, 2024
Mintz’s intellectual property litigation group was named “Litigation Department of the Year” for the IP specialty category in the 2024 New England Legal Awards. The awards recognize attorneys and firms in Connecticut, Maine, Vermont, New Hampshire, Massachusetts, and Rhode Island.
Defending AI, Machine Learning Patents In Life Sciences
October 1, 2024
Intellectual Property Chair Michael Renaud and Associates Meena Seralathan, Simone Yhap, and Williams Dixon recently wrote an article for Law360 focused on protecting artificial intelligence and machine learning patents in the life sciences industry following the US Supreme Court’s 2014 decision in Alice v. CLS Bank.